Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology

Pharmazie

Volumn 65, Issue 2, 2010, Pages 93-96

  Nomura, T ^a   Abe, Y ^a   Kamada, H ^a   Inoue, M ^a   Kawara, T ^a   Arita, S ^a   Furuya, T ^a   Minowa, K ^a   Yoshioka, Y ^a   Shibata, H ^a   Kayamuro, H ^a   Yamashita, T ^a   Nagano, K ^a   Yoshikawa, T ^a   Mukai, Y ^a   Nakagawa, S ^a   Tsunoda, Shin Ichi ^a   Tsutsumi, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; MUTANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1 ANTAGONIST; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; DRUG ISOLATION; HUMAN; HUMAN CELL; PHAGE DISPLAY; PROTEIN VARIANT; RECEPTOR BINDING;

CELL LINE; CELL SURVIVAL; FIBROBLASTS; GENETIC VARIATION; HUMANS; MUTATION; PEPTIDE LIBRARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTORS;

EID: 76149137723     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9265     Document Type: Article

References (23)

1. Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda S, Tsutsumi Y (2008) Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J Immunol Methods 335: 71-78.
2. Aggarwal BB(2003) Signalling pathways of the TNF superfamily: a doubleedged sword. Nat Rev Immunol 3: 745-756.
3. Brown SL, Greene MH,Gershon SK,Edwards ET,Braun MM(2002)Tumor necrosis factor antagonist therapy and lymphoma development: twentysix cases reported to the Food and Drug Administration. Arthritis Rheum 46: 3151-3158.
4. Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2: 364-371.
5. Goldbach-Mansky R, Lipsky PE (2003) New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 54: 197-216.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD(2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127.
7. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P (1998) TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28: 257-263.
8. Imai S, Mukai Y, Takeda T, Abe Y, Nagano K, Kamada H, Nakagawa S, Tsunoda S, Tsutsumi Y (2008) Effect of protein properties on display efficiency using the M13 phage display system. Pharmazie 63: 760-764.
9. Kim EY, Priatel JJ, Teh SJ, Teh HS (2006) TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176: 1026-1035.
10. Kim EY, Teh HS (2001) TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 167: 6812-6820.
11. Kollias G,KontoyiannisD(2002) Role of TNF/TNFR in autoimmunity: specificTNFreceptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13: 315-321.
12. Lubel JS, Testro AG, Angus PW (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 37: 705-712.
13. Mori L, Iselin S, De Libero G, Lesslauer W(1996) Attenuation of collageninduced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157: 3178-3182.
14. Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y (2009) Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 385: 1221-1229.
15. Nagano K, Imai S, Mukai Y, Nakagawa S, Abe Y, Kamada H, Tsunoda S, Tsutsumi Y (2009) Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library. Pharmazie 64: 238-241.
16. Nomura T, Kawamura M, Shibata H, Abe Y, Ohkawa A, Mukai Y, Sugita T, Imai S, Nagano K, Okamoto T, Tsutsumi Y, Kamada H, Nakagawa S, Tsunoda S (2007) Creation of a novel cell penetrating peptide, using a random 18mer peptides library. Pharmazie 62: 569-573.
17. Olleros ML, Guler R, Corazza N,Vesin D, Eugster HP, Marchal G, Chavarot P, Mueller C, Garcia I (2002) Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168: 3394-3401.
18. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
19. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ (2005) Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174: 4852-4859.
20. Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y (2004) Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 10: 8293-8300.
21. Shibata H, Yoshioka Y, Ohkawa A, Abe Y, Nomura T, Mukai Y, Nakagawa S, Taniai M, Ohta T, Mayumi T, Kamada H, Tsunoda S, Tsutsumi Y (2008a) The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 44: 229-233.
22. Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, Taniai M, Nomura T, Kayamuro H, Nabeshi H, Sugita T, Imai S, Nagano K, Yoshikawa T, Fujita T, Nakagawa S, Yamamoto A, Ohta T, Hayakawa T, Mayumi T, Vandenabeele P, Aggarwal BB, Nakamura T, Yamagata Y, Tsunoda S, Kamada H, Tsutsumi Y (2008b) Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 283: 998-1007.
23. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T (2003) Sitespecific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21: 546-552.